Greenwich LifeSciences Files 8-K: Material Agreement & Equity Sales

TL;DR

GLSI signed a big deal and sold some stock, more details to come.

AI Summary

Greenwich LifeSciences, Inc. announced on June 13, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement, sales, or financial figures were not provided in this initial filing.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial position and future operations.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks depending on the specifics not yet disclosed.

Key Players & Entities

• Greenwich LifeSciences, Inc. (company) — Registrant
• June 13, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Stafford, TX (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value GLSI The Nasdaq Stock Mar
• $14.30 — .001 per share, at an offering price of $14.30 per share which was the Nasdaq Official
• $2.5 m — ds from the offering were approximately $2.5 million, prior to deducting offering expe

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex10-1.htm (EX-10.1) — 200KB
• 0001493152-24-024035.txt ( ) — 456KB
• glsi-20240613.xsd (EX-101.SCH) — 3KB
• glsi-20240613_lab.xml (EX-101.LAB) — 33KB
• glsi-20240613_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 13, 2024, Greenwich LifeSciences, Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with Snehal Patel, its Chief Executive Officer, pursuant to which the Company agreed to issue and sell to Mr. Patel, in a private placement, 174,825 shares (the " Shares ") of its common stock, par value $0.001 per share, at an offering price of $14.30 per share which was the Nasdaq Official Closing Price on June 12, 2024. The Shares sold in the Private Placement are being issued as restricted securities as defined in Rule 144 of the Securities Act of 1933, as amended and do not contain any registration rights. The gross proceeds from the offering were approximately $2.5 million, prior to deducting offering expenses payable by the Company. The Company intends to use the net proceeds for clinical development and working capital. The closing of the private placement is expected to occur on June 18, 2024, subject to the satisfaction of customary closing conditions. The foregoing descriptions of terms and conditions of the Purchase Agreement do not purport to be complete and are qualified in their entirety by the full text of the form of the Purchase Agreement attached hereto as Exhibit 10.1 to this Current Report on Form 8-K and are incorporated by reference herein. Item 3.02 Unregistered Sales of Equity Securities. Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference. The Shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy these securities,

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits. 10.1 Form of Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Greenwich LifeSciences, Inc. Date: June 17, 2024 By: /s/ Snehal Patel Snehal Patel Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR